Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE ...

Like several other biopharmas before it, UCB has turned to perhaps the most recognizable dermatologist in the U.S. to add ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of €240.00. The company’s shares closed last ...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this ...

It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); ...

Shares of major European drugmakers fell Wednesday morning after U.S. President Donald Trump reaffirmed plans to impose a "major" tariff on all pharmaceutical imports.

A Section 232 probe may delay pharma tariffs until late 2025 or beyond. Markets are messy—but the right setups can still deliver triple-digit gains. Join Matt Maley live this Wednesday at 6 PM ...

UCB Pharma Inc. has presented new preclinical data on their anti-α-synuclein antibody UCB-7853 for the potential treatment of PD.

TOB has received research support from the Epilepsy Society of Australia, National Health and Medical Research Council, Royal Melbourne Hospital Neuroscience Foundation, Sanofi-Aventis, UCB Pharma, ...